- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Topical ointment for psoriasis therapy gets FDA's NDA nod
Washington -- The Food and Drug Administration has approved the new drug application (NDA) for Taclonex, a topical ointment for the treatment of psoriasis vulgaris in adults.
Washington -- The Food and Drug Administration has approved the new drug application (NDA) for Taclonex, a topical ointment for the treatment of psoriasis vulgaris in adults. Taclonex is sold outside the United States as Dovobet and Daivobet.
Officials of Warner Chilcott, Danish drug company LEO Pharma's exclusive licensee of Taclonex in the United States, say they expect to launch the drug in the first half of this year.
More than 4.5 million adults in the United States have been diagnosed with psoriasis, and about 150,000 new cases are diagnosed annually.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
